Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast


Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Pharmaceutical Drug Production in Russia (October 2022)

Thursday, November 24, 2022

In January–October 2022, Russian manufacturers produced 579.5 billion rubles’ worth of ready-made drugs (manufacturer’s prices, VAT included), up 18.5% from the same period in 2021. As usual, the high inflation rate played a significant role here, especially since it has been 10% or higher since March. In physical terms, the production volume was 3.44 billion packages, up 2.9% from January–October 2021. If calculated in minimum dosage units (MDU), the volume was 65.4 billion MDUs, up 2.1% from the same period last year.

October 2022 saw a decline in manufacture in both monetary and physical terms for the first time in 2022. Russian manufacturers produced 51.4 billion rubles’ worth of pharmaceuticals, down 9% from October 2021. In physical terms, the growth rate was –3.3% in packages (in September 2022, it was negative as well, –2%), with 350 million packages manufactured. In MDUs, the growth rate in monetary terms was –2.3%, which is the fourth time in 2022 the growth rate in MDUs is negative.

The production of OTC drugs had the best growth rates in January–October 2022, up 10.4% in packages. The product range kept expanding, and the total number of INNs produced went up from 433 in January–October 2021 to 467 in January–October 2022. A combined remedy of clove oil, camphor, peppermint oil and eucalyptus oil, Geucamen, had the best growth rates—its manufacture increased 21.6 times against January–October 2021. The product was manufactured by two companies, with the Tula Pharmaceutical Factory contributing to the growth rates the most. The production of the INN estriol increased 13.7 times against January–October 2021; it was manufactured by three companies, and Vertex with its Orniona helped the total growth rates the most. Estriol is followed by glutamic acid—its production (by Tatchempharmpreparaty) went up 12.4 times against the comparison period.

As for prescription drugs, the product range was twice the number of OTC drugs—976 INNs, 36 from January–October 2021. However, the growth rates were negative, –5% in packages. The production of ixazomib had the highest growth rates. It was manufactured only in the form of the localized drug Ninlaro by Takeda and packaged at the company’s enterprise in Yaroslavl. Ixazomib is followed by amikacin (manufacture grew 15.7 times against January–October 2021). Three Russian pharmaceutical companies produced drugs under this INN, with Kraspharma contributing to the growth rates the most. Cyproterone rounds out the top three (manufacture went up 15.4 times), produced only by Pharmasyntez this year, in the form of the antiandrogenic drug Antiandren.

Pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (packages) and monetary terms (RUB, VAT included) (January 2021–October 2022)